Tango Biosciences

Executive Summary

Tango Biosciences is a US-based contract research organization (CRO) specializing in phage display technology, founded in 2016 and headquartered in Cambridge, Massachusetts. The company offers custom affinity reagents, binding assay development, and peptide drug discovery services to biotech and pharmaceutical clients. By leveraging its expertise in phage display, Tango enables precision research tools, diagnostics, and therapeutic candidates. As a private CRO, the company operates in the competitive synthetic biology and genomics space, focusing on high-value custom services. While financial details are not publicly disclosed, Tango is well-positioned to benefit from the growing demand for specialized biologics discovery and development services. The company's differentiated technology platform and experienced team could drive future growth, but its small size and private status limit visibility. Overall, Tango represents a niche player in the CRO market with potential for steady expansion.

Upcoming Catalysts (preview)

• Q3 2026Launch of novel phage display platform for difficult targets70% success
• Q4 2026Strategic partnership with a mid-size biotech for therapeutic discovery60% success
• 2027Expansion of service offerings into next-generation sequencing coupling40% success